NCT07055321View on ClinicalTrials.gov

A Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

July 8, 2024

Study Completion Date

July 8, 2024

Conditions
Healthy Subjects
Interventions
DRUG

ETH47

Dose level 1; single intranasal administration

DRUG

ETH47

Dose level 2; single intranasal administration

DRUG

ETH47

Dose level 3; single intranasal administration

DRUG

ETH47

Dose level 4; single intranasal administration

DRUG

ETH47

Dose level 5; single intranasal administration

DRUG

ETH47

Dose level 1; single inhaled administration

DRUG

ETH47

Dose level 2; single inhaled administration

DRUG

ETH47

Dose level 3; single inhaled administration

DRUG

ETH47

Dose level 4; single inhaled administration

Trial Locations (1)

Unknown

CRO, Merthyr Tydfil

Sponsors

Lead Sponsor

Ethris GmbH
All Listed Sponsors
lead

Ethris GmbH

INDUSTRY

NCT07055321 - A Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants | Biotech Hunter | Biotech Hunter